Header
Events & presentations.
Browse the calendar to view investor-related events and announcements. Webcasts and presentations that have been archived are available by viewing past event details.
- Upcoming Events
- Past Events
- Open a printable version of this page
- Email the URL of this page to a friend
- Get the RSS feed for this page
Subscribe Header
Receive updates straight to your inbox
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources , and more. Learn More
NASDAQ: KPTI
Karyopharm therapeutics.
KPTI earnings call for the period ending June 30, 2024.
Image source: The Motley Fool.
Karyopharm Therapeutics ( KPTI -3.56% ) Q2 2024 Earnings Call Aug 06, 2024 , 8:00 a.m. ET
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Good morning. My name is Carolyn, and I will be your conference operator today. At this time, I would like to welcome everyone to Karyopharm Therapeutics second quarter 2024 financial results conference call. There will be a question-and-answer session to follow.
Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Elhan Webb, senior vice president, investor relations.
Elhan Webb -- Senior Vice President, Investor Relations
Thank you, Carolyn, and thank you all for joining us on today's conference call to discuss Karyopharm's second quarter Q2 2024 financial results and recent company progress. We issued a press release this morning detailing our financial results for Q2 2024. This release, along with a slide presentation that I will reference during our call today are available on our website. For today's call, as seen on Slide 2, I'm joined by Richard, Reshma, Sohanya and Mike will provide an update on our results for Q2 2024 and recent clinical developments.
Before we begin our formal comments, I'll remind you that various remarks will make today constitute forward-looking statements, FLS for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on Slide 3. Actual results may differ materially from those indicated by this FLS as a result of various important factors, including those discussed in the Risk Factors section of our most recent Form 10-Q, which is on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represent our views as of today only. While we may elect to update these FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change.
Therefore, you should not rely on these FLS as representing our views as of any later date. I will now turn the call over to Richard. Please turn to Slide 4.
Richard Paulson -- Chief Executive Officer
Good morning. Thank you, Elhan, and thank you all for joining us today for Karyopharm's Q2 2024 earnings call. Turning to Slide 5. I would like to first focus on our innovation and growth strategy as we work to deliver our next stage of growth by advancing our late-stage pipeline while continuing to strengthen our foundation in multiple myeloma.
Starting with myelofibrosis, we are more excited than ever regarding SELINEXOR's potential opportunity in this indication. Physician interest in enrolling patients into our Phase III study is strong and the competitive environment continues to evolve favorably for us. Building on our strong clinical data, the new preclinical data that we presented at EHA further reinforces the role that SELINEXOR might play in myelofibrosis. In endometrial cancer, we presented updated data at ASCO, demonstrating nearly 40 months of progression-free survival when SELINEXOR is used as a maintenance therapy in patients whose tumors are TP53 wild-type/pMMR.
This population represents approximately half of all patients who are diagnosed with endometrial cancer. It is noteworthy that the progression-free survival that SELINEXOR is demonstrating in the maintenance setting in this subgroup exceeds the overall survival that is achieved by the checkpoint inhibitors in patients whose tumors are CMMR. As we continue to enroll patients in our EC-042 Phase III trial in endometrial cancer, we are also confronting the complexities of a molecularly targeted maintenance trial and are taking proactive actions, both of which Reshma will expand on. As a result, we now expect to deliver top line data in early 2026.
In multi-myeloma, we are pleased to report our second consecutive quarter of growth in XPOVIO revenue, giving us confidence to raise the low end of our revenue guidance for 2024. The importance of XPOVIO's differentiated mechanism of action, its all oral administration and potentially T cell sparing impact is increasingly resonating with community and academic physicians, which Sohanya will expand on. As we work to build on our commercial foundation of multi-myeloma, we expect to leverage our positively evolving SPD data at the 40-milligram dose to update the design of the Phase III EMN29 trial, which will include targeting fewer participants for enrollment and lowering the projected cost of this trial. Finally, in light of our strengthening commercial performance, disciplined cost management and focused approach to clinical development, we believe we're in a strong financial position to deliver on our prioritized late-stage pipeline.
Mike will expand on our lowered 2024 R&D and SG&A expense guidance. We continue to be very optimistic about our next stage of growth and are well positioned to capitalize on the opportunities for SELINEXOR with our diversely built late-stage pipeline across three different cancer indications. We continue to believe the annual peak revenue opportunity for SELINEXOR could be $2 billion in the U.S. alone.
I would now like to turn the call over to Reshma to expand on our recent data announcements and discuss our progress with each of the programs in our pipeline. Reshma?
Reshma Rangwala -- Chief Medical Officer and Head of Research
Thank you, Richard. Turning to Slide 7. I'd like to highlight our promising late-stage pipeline led by SELINEXOR's three ongoing Phase III studies, each of which has the potential to enable a new standard of care, continuing to build upon the growing body of data and utilizing the once-weekly lower doses of either 40 or 60 milligrams. We continue to be very encouraged by the data generated to date supporting our three pivotal Phase III trials, including the improving long-term follow-up data in endometrial cancer from the exploratory subgroup analysis in the SIENDO trial that was presented at ASCO, which I'll expand on shortly.
Starting with myelofibrosis on Slide 9. We are incredibly excited by both our evolving data and physician interest in our work in this area. In June, we presented new preclinical data at the European Hematology Association Hybrid Congress. These data demonstrated the strong mechanistic rationale of XPO1 inhibition in myelofibrosis and its ability to target both the JAK and non-JAK pathways.
In light of our data that shows that XPO1 inhibits both JAK and non-JAK pathways, we believe that SELINEXOR can be leveraged both in combination and as a monotherapy. We presented data from our Phase I trial in myelofibrosis last year, as seen on Slide 10. SELINEXOR 60 milligrams was evaluated in combination with ruxolitinib in JAK inhibitor naive patients. Of the 14 patients who received the 60-milligram dose of SELINEXOR, 79% and 58% achieved a SVR35 and TSS50 at week 24, respectively.
Absolute TSS demonstrated very meaningful improvements with an average reduction of 18.5 points at week 24 in the efficacy evaluable population. Diving deeper into the important aspect of durability on Slide 11. As of the data cutoff, there was 100% probability of continuing responses in both the SVR35 and TSS50 over a median duration of follow-up of 32 weeks and 51 weeks, respectively, when SELINEXOR 60 milligrams was used in combination with ruxolitinib indicating that the responses are maintained well beyond 24 weeks. These findings support the potential of the combination of SELINEXOR plus ruxolitinib to offer greater symptom improvement than ruxolitinib alone as our ongoing Phase III study may demonstrate.
Moving to Slide 12, we outlined the trial design for our Phase III SENTRY trial, evaluating the combination of SELINEXOR 60 milligrams with ruxolitinib compared to ruxolitinib alone in 306 JAK-naive myelofibrosis patients. We are encouraged by the strong enrollment into our Phase III clinical trial, given by the positive feedback that we are hearing from clinical trial investigators regarding SELINEXOR's unique mechanism and clinical profile. Our momentum is also fueled by minimal competitive clinical activity and paucity of effective therapies. Our guidance for reporting top line results remains firmly on track for the second half of 2025.
Turning our attention to endometrial cancer on Slide 14. One of SELINEXOR's primary mechanisms is to suppress the export of P53 from the nucleus to the cytoplasm. The accumulation of p53 in the nucleus leads to impaired DNA repair, cell-cycle arrest and ultimately increased apoptosis. Clinically, this mechanism is what drives antitumor activity in tumors dependent upon p53, including endometrial cancer.
Advanced in recurrent endometrial cancer is the most common form of gynecologic cancer in the United States with approximately 16,000 patients diagnosed each year. We believe SELINEXOR could play an important role for greater than half of these patients as the first novel oral maintenance therapy for patients with TP53 wild-type tumors. As seen on Slide 15, TP53 wild-type status has an emerging role in the evolving landscape of advanced and recurrent endometrial cancer. Checkpoint inhibitors were recently improved by the FDA in combination with chemotherapy, followed by checkpoint inhibitor maintenance for advanced recurrent endometrial cancer patients regardless of MMR status.
However, the efficacy observed in patients whose tumors are pMMR is markedly less than in the dMMR consistent with the mechanistic rationale for checkpoint inhibitor effectiveness in dMMR solid tumors. These checkpoint inhibitors have been included in combination with chemotherapy, followed by checkpoint inhibitor maintenance in the NCCN guidelines for all patients regardless of MMR status since March of 2023. Patients whose tumors are both pMMR and p53 wild-type represent roughly 50% of all advanced or recurrent endometrial cancer patients. Turning to Slide 16.
At ASCO, we presented very encouraging long-term follow-up data from the exploratory analysis of SIENDO, which evaluated SELINEXOR and maintenance therapy. Patients with p53 wild-type TMMR tumors experienced a median PFS of 39.5 months with SELINEXOR compared to 4.9 months with placebo, resulting in a hazard ratio of 0.36. Acknowledging the limitations in cross-trial comparisons, the median PFS improvement achieved with SELINEXOR in the subgroup exceeds the median overall survival achieved by checkpoint inhibitors in pMMR patients, underscoring the meaningful efficacy achieved with SELINEXOR in these patients. In all patients with p53 wild-type tumors, SELINEXOR demonstrated promising benefit with a median PFS of 28.4 months compared to 5.2 months for placebo, resulting in a hazard ratio of 0.44.
These robust exploratory subgroup data from SIENDO continued to demonstrate the potential of SELINEXOR to provide substantial benefit in a unique and sizable population. In a survey of U.S. physicians who were provided long-term follow-up data achieved with SELINEXOR in patients with -- whose tumors are p53 wild type from the SIENDO study, as well as efficacy with the checkpoint inhibitors, 75% indicated future intent to prescribe SELINEXOR as a maintenance therapy for p53 wild-type pMMR endometrial cancer patients. Overall, we believe that SELINEXOR were to be approved in this indication, a majority of patients could benefit from this treatment option.
Let's also review the updated safety data on endometrial cancer from the SIENDO trial that we presented at ASCO, as shown on Slide 17. Adverse events were generally manageable and well tolerated. The most common AEs observed with SELINEXOR, regardless of grade, were nausea of vomiting and diarrhea. It is important to note that dual antiemetics were not required in this trial.
Grade 3-plus treatment emergent adverse events were rare with the most common events being neutropenia, thrombocytopenia and nausea. Finally, on Slide 18, and as Richard mentioned, we are shifting our expected time line for the top line data readout for our pivotal export EC-042 Phase III trial to early '26. Based on recent observations and increasing interval between biopsy evaluation and chemotherapy completion has led to a higher-than-expected screen failure rate. Availability of new therapies is also impacting our enrollment, albeit to a lesser degree.
Based upon these observations, we are enhancing our investments by adding additional sites to increase the total number of patients that will need to be screened for this trial. Overall, I continue to be extremely enthusiastic about the potential for SELINEXOR to provide clinically meaningful outcomes in the maintenance setting for patients with p53 wild-type endometrial cancer, especially those with pMMR tumors, where our exploratory subgroup data has demonstrated a median PFS of nearly 40 months, which again exceeds the median overall survival observed with checkpoint inhibitors in patients with pMMR tumors. Lastly, turning to multiple myeloma on Slide 20. We are very encouraged with the results from our STOMP and MM-028 trials that evaluated SELINEXOR 40 milligrams in combination with pomalidomide, and dexamethasone.
The promising data published in the Frontiers of Oncology journal in May of this year underscores SELINEXOR's potential to expand its position in the multiple myeloma landscape. Selinexor 40 milligrams demonstrated an updated median PFS of 18.4 months and a very tolerable safety profile. Nausea rates were observed in only 32% of patients in the 40-milligram arm, a meaningful improvement relative to the 50% that was observed with SELINEXOR 100 milligram in the BOSTON trial. Our ongoing Phase III trial has the potential to build upon and improve the already favorable data, given that the STOMP and MM-028 cohorts did not require dual antiemetics.
Our Phase III EMN29-SPD trial in multiple myeloma is outlined on Slide 21. This trial is designed to address the unmet need present in patients with multiple myeloma with an all-oral triplet treatment option that can be beneficial to pre- and post-T-cell engaging therapies. We will be working with the European myeloma network, the sponsor of the study, to leverage the positively evolving PFS data observed with SPD-40 and amend the statistical analysis plan to enable a meaningful interpretation of the efficacy and safety of SPD versus EPD. Importantly, we are also seeing a slowdown in enrollment rates due to an increasingly global competitive trial environment with an increased number of Phase III studies targeting the same sites in a similar patient population.
In fact, as of today, four large Phase III trials have already been initiated in 2024, the same number of trials initiated in all of 2023. We now plan to enroll approximately half of the planned sample size and pending the strength of the data, we will engage with regulatory agencies accordingly. Based upon these revised plans, we continue to anticipate top line results in the first half of 2025. In conclusion, our rapidly advancing pipeline presents near-term late-stage opportunities backed by increasingly compelling data.
SELINEXOR has the potential to benefit multiple cancer patient populations with high unmet needs in the near future, enhancing our existing approved indications in multiple myeloma. I will now turn the call to Sohanya for a review of our commercial highlights.
Sohanya Cheng -- Senior Vice President of Sales and Commercial Operations
Thank you, Reshma, and good morning, everyone. On Slide 23, I will discuss our commercial highlights for the second quarter of 2024. In the second quarter, XPOVIO net product revenue was $28 million, up 8% compared to our results in the first quarter. Consecutive quarter-over-quarter growth was driven by growth in both new patient starts and refills as XPOVIO is increasingly utilized in a flexible position across the treatment paradigm as a convenient oral regimen with a differentiated mechanism of action.
The results and momentum from the first half of this year and continued strong execution have led us to raise the low end of our net product revenue guidance by $5 million to a new range of $105 million to $120 million. New patient mix remained stable in the second to fourth treatment lines with earlier line use primarily coming from the community setting, which contributed to approximately 60% of XPOVIO net revenues in the second quarter. Demand in the community setting grew more than 10% from the first quarter. Demand in the academic setting remained consistent with the first quarter, with XPOVIO being increasingly used immediately before or after T cell therapies as a way to potentially preserve T cell fitness.
In academic institutions using XPOVIO as a bridging regimen prior to T-cell therapy use, we see shorter duration of therapy of XPOVIO, but this was offset by the increase in new starts in this setting. Overall, in a highly competitive marketplace, we are very pleased with the results that our commercial organization has delivered in the first half of the year with consecutive quarter-over-quarter growth. Now, I'd like to turn to Slide 24 and shift our focus toward milestones accomplished outside of the U.S. I'm pleased with our momentum as we expand our global footprint with continued regulatory and reimbursement approvals of SELINEXOR across the world.
In the second quarter, following the positive recommendation from NICE, expanded reimbursement was achieved in the U.K., as well as South Korea. Additionally, XPOVIO continued to expand its global footprint with additional regulatory approvals in China and other international markets. In summary, Karyopharm's multiple myeloma franchise continues to impact an increasingly number of patients globally while remaining a profitable business and serving as a critical driver in funding our pipeline. A dedicated commercialization team and partners have the capability for rapid launches in potential future indications as well.
Now, I'd like to turn the call over to Mike to give an update on our financials.
Mike Mason -- Chief Financial Officer
Good morning, everyone, and thank you, Sohanya. Turning to our financials since we issued a press release earlier today with the full financial results, I will just focus on the highlights, which are on Slide 26. And Total revenue for the second quarter of 2024 was $42.8 million, reflecting strong momentum compared to $37.6 million for the second quarter of 2023. Net U.S.
XPOVIO revenue for the second quarter of 2024 was $28 million compared to $28.5 million for the second quarter of 2023. The gross to net discount for XPOVIO in the second quarter of 2024 was 29% as compared to 22% in the second quarter of 2023. This was driven by increased 340B utilization, Medicare rebates and expired product returns. We continue to expect 25% to 30% GTN for the full year 2024.
Our total expenses for the second quarter of 2024 were up slightly year over year by 6%, driven by our investments in our late-stage clinical pipeline with three ongoing Phase III trials. R&D expenses for the second quarter of 2024 were $38.4 million compared to $31.5 million for the second quarter of 2023. The increase in R&D expenses is primarily attributable to higher clinical trial costs related to our pivotal Phase III programs. SG&A expenses for the second quarter of 2024 were $31 million compared to $34.5 million for the second quarter of 2023.
The decrease in SG&A expenses was primarily due to ongoing cost reduction initiatives and lower headcount, partially offset by approximately $1 million in debt financing-related expenses. We reported net income of $23.8 million for the second quarter of 2024 compared to a net loss of $32.6 million for the second quarter of 2023. Mostly due to a onetime noncash net gain of $44.7 million on the extinguishment of debt and $14.3 million in gains that were recognized in connection with the refinancing transactions that we concluded in May, which you can see in detail on the related slide in the appendix. As a reminder, these transactions extended the vast majority of our maturities into '28 and '29, well beyond our expected data readouts from our three Phase III trials and potential launches.
Cash, cash equivalents, restricted cash and investments as of June 30, 2024, totaled $152.5 million compared to $192.4 million as of December 31, 2023. Based on our current operating plans, we are raising the lower end of our guidance for both total revenue and XPOVIO net product revenue by $5 million and lowering and tightening our overall range of expense guidance by $10 million to $15 million. The operating expense reductions for the remainder of 2024 include lower expected expenses for EMN 29 trial with the planned resizing, as well as continued discipline in our operating costs, including headcount. Specifically, since the beginning of last year, we have reduced our budget headcount by approximately 30%.
Our updated guidance ranges for the full year of 2024 are as follows: Total revenue expected to be in the range of $145 million to $160 million as compared to previous guidance of $140 million to $160 million. XPOVIO net U.S. product revenue is expected to be in the range of $105 million to $120 million as compared to the previous guidance of $100 million to $120 million. We are also lowering our expense guidance for the full year of 2024 as follows: R&D and SG&A expense is expected to be in the range of $250 million to $265 million, which includes approximately $20 million of estimated noncash stock-based compensation expense as compared to previous guidance of $260 million to $280 million.
And finally, we expect our existing cash, cash equivalents and investments, as well as the revenue we expect to generate from XPOVIO net product sales and other license revenues will be sufficient to fund our planned operations into Q1 2026. Note that our cash runway does not include paying up the remaining 2025 convertible notes and our $25 million minimum liquidity covenant under the new term loan. We expect our 2025 operating expenses to be lower than 2024 as we recognize the full year benefits of our ongoing cost-saving initiatives. In summary, we are focused on the advancement of our three Phase III trials and driving commercial performance while continuing to be very diligent when allocating our resources.
I'll now flip to Slide 27 and turn the call over to Richard for some final thoughts. Richard?
Thank you, Mike. As you can see on Slide 28, we have several meaningful milestones ahead of us in the near future. We believe our continued focus on disciplined capital allocation and expense management provides us with cash runway to achieve these milestones. We are enthusiastic about our innovation and growth strategy, which provides us valuable optionality with our Phase III clinical trials in myelofibrosis, endometrial cancer and multi myeloma.
These trials have the potential to bring transformative benefits to patients and drive substantial progress for our company. As a company, we will continue to strive toward unlocking SELINEXOR's full potential as we execute in a disciplined manner and deliver on our next phase of growth. Thank you again for joining us today, and I would now like to ask the operator to open the call up to the Q&A portion of today's call. Operator?
Questions & Answers:
Thank you. [Operator instructions] One moment please for your first question. Our first question is from Peter Lawson from Barclays.
Unknown speaker -- Barclays -- Analyst
Hey, good morning. This is Alex on for Peter. Thank you for taking our questions. I just wanted to -- I was wondering if you could expand a little bit on what is driving the change in time lines for the endometrial trial and the higher screen failure rates? And beyond adding additional sites, are there any other changes being implemented in the trial here?
Yes. Thanks, Alex. I'll turn to Reshma for that and really, I think she highlighted it at a high level, but to go into some more detail when we look at kind of the learnings we have in the endometrial trial and what's happening and how we're addressing it. So I'll turn that to Reshma.
Yes. Thank you. So I want to start off in the endometrial space, just highlighting the data that we have observed with SELINEXOR in this unique population defined by their p53 status. We first presented long-term data back in July of 2023.
This was part of the ASCO plenary series. It was really important to note, especially from one of the moderators who describe the data is truly unprecedented. And it underscores the benefit that SELINEXOR can achieve in this patient population defined by p53 status. Those data have only gotten stronger.
In fact, at ASCO, SELINEXOR in this population -- In those patients who are defined by both p53 wild-type and pMMR status, their data now show an unprecedented 40-month median PFS. That 40 months actually exceeds the overall survival observed with the checkpoint inhibitors in that pMMR patient population -- you are correct. We are seeing challenges in our enrollment. One of the main drivers, and it's a recent observation is this increase in screen failure rate, and it's very unique to a biomarker it's a driven trial.
I say that because many of the physicians are submitting their biopsies relatively early during the chemotherapy process. That biopsy is evaluated by physicians for that p53 status. With that said, even if that biopsy is evaluated as p53 wild-type, those patients need to complete months of chemotherapy. And during that time, we have been seeing that they can screen fail for a myriad of reasons, whether it's for lab reasons, scan reasons, they may need to have surgeries, they may decide that they don't ultimately want to participate in a clinical trial.
Those reasons contribute to that higher screen fail rate. And as such, we are actively looking at multiple initiatives, increase the total pool of patients that we can screen the major initiative is going to be activating new sites in our current existing countries and potentially in new additional countries. Other initiatives that we are looking at is, of course, doubling down on our medical affairs support looking at outside vendors, we continue to partner very closely with the GOG and ENGOT. Ultimately, we are committed to completing enrollment of this trial and updating everybody on top line results in early 2026.
Great. That's helpful. Thank you very much.
Thanks, Alex.
The next question will be coming from Maurice Raycroft from Jefferies.
Maury Raycroft -- Analyst
Hi. Thanks for taking my questions. Maybe just a quick follow-up to the last one. Are you saying anything more about how many new sites you anticipate opening and what regions you plan on opening those sites in?
Yes. Thanks for the question, Maury. No, we're not providing any additional color on those details just primarily looking at opening up some new sites in our existing countries and like I said, potentially additional countries and then continuing to support the many sites that have already been activated in our current trial. So I think those main focus really will enable that increased screening pool that we need to achieve to enable those top line results in the first -- in early 2026.
Got it. And is there any way to potentially help mitigate the issue with the biopsy process? I guess, can Karyopharm do anything to help on that front? And then, could part of the outcome of this lead to an enrichment of the p53 wild-type pMMR population? Or how are you thinking about that?
So I will say the biopsy process is already going very smoothly. In endometrial cancer, molecular classification is really becoming the standard of care, both because physicians are evaluating the MMR status. -- as well as other biomarker classifications, including p53, Poli, etc. So physicians are really used to evaluating biopsies in the case of our clinical trial.
They just submit that biopsy to Foundation Medicine. They process it very quickly, and the results are turned around within a matter of days. The main driver specific to our trial is again that interval between when the biopsy is submitted in the months of chemotherapy that they still need to complete. And that, unfortunately, is nothing -- there's nothing that we can do to offset that process.
In terms of your second question, it's a good one. And I think like naturally, we are going to see patients who are pMMR, as well as p53 wild type based upon local testing disproportionately submitting tumors to SMI. So I think we will see that rate rise over time.
OK. Thanks for taking my questions. I'll hop back in the queue.
Thanks, Maurice.
Next question will be coming from Colleen Kusy from Baird.
Colleen Kusy -- Analyst
Hi. Good morning. Thanks for taking our questions. Among those enrolled another question on the endometrial study.
Can you comment on any sort of PFS metrics so far and how that's tracking versus your expectation? And whether kind of enrolling some of these pMMR p53-wild-type patients might be pushing out the data as well, just given how long -- how strong the CNO data has been?
Yes. Thanks for the question, Colleen. So no, we do not have any insight in terms of the results from this trial. It's a double-blinded trial.
We also are very much blinded to the results across either one of these arms. So no insight there. I think I'll just go back to the SIENDO data in that p53 wild-type subgroup that we've had an opportunity to report on multiple times. That data just continues to get stronger, right? In that large p53 wild-type subgroup, we are now seeing a median PFS of 28.4 months.
And I'll reiterate in that p53 wild-type TMMR subgroup, those data now demonstrated a median PFS of 40 months, truly unprecedented data and really underscores the strength of the benefit that can be achieved with SELINEXOR we've incorporated those PSS into our assumptions. So we assume a very meaningful PFS benefit at the time of the top line results and again, has already been incorporated into the projections that inform that early 2026 top line result readout.
Got it. That's helpful. And then, on the screen failure rate, can you comment if the TP53 wild-type biomarker is roughly as prevalent as you thought it was so far in the screening process? Is it still roughly around 50%?
Yes, it is. It is sitting nicely in that assumed rate of more than half of all patients.
Great. And then, one commercial question, if I can. Sohanya, can you just give us a sense of the duration of treatment for the pre- and post T cell therapies you're seeing in the academic centers? Is it like a one month or maybe low single digits, but just kind of help us get a range on that, please?
Yes. Thanks, Colleen. So we don't disclose exact months of duration because we have to triangulate multiple data sources, it takes time for that to mature. However, take a step back and look at trends overall, obviously, we see a long-term trend since the launch of the drug in terms of increasing duration.
The recent dynamics in the competitive landscape, obviously, with bridging and post T cell therapies have obviously impacted duration, but this is a smaller proportion of our patients. The large majority of our patients remain in the early align, second, third and fourth line -- and really, that helped to propel our duration up.
Great. Thanks for taking our questions.
Thanks, Colleen.
Next on the line is coming from Brian Abrahams from RBC.
Brian Abrahams -- Analyst
Hi. Good morning. Thanks for taking my questions. Maybe shifting gears to myelofibrosis.
The Phase III 034 study is based on some of the data you presented on Slide 10, where you showed quite robust benefits for SELINEXOR on top of rux, but in a relatively small number of patients. So I guess I'm curious, as the trial is continuing, if there may be any opportunities to adjust the powering or design of the study based on the ongoing data or on regulatory outcomes from Pelabresib the late-stage drug that's also in development. And then, maybe secondarily, on MF, it looked like the SELINEXOR monotherapy study was -- time line was pushed out just a bit there. Just wondering if you could tell us kind of how that study is going and the extent of the data we should be looking for now in the back -- at the end of this year or early next?
Thanks for the question. So we're -- we remain really confident about myelofibrosis. I think as you mentioned, the strength of the data are unparalleled. And the reason I say that is because, yes, although we have a smaller cohort of patients in which we evaluated the efficacy with SELINEXOR plus ruxolitinib, specifically a 79% SVR35 rate and a 58% TSS50 rate at week 24, it only builds upon the data that we have evaluated with not only SELINEXOR but the combination, I underscore the preclinical data, the mechanistic data that really suggests that SELINEXOR in XPO1 inhibition is targeting both JAK and non-JAK pathways, as well as the totality of the data that really suggests that when SELINEXOR is combined with ruxolitinib, you can see additive, if not synergistic effects.
Layer on now the clinical data that have demonstrated monotherapy activity. This goes back to the essential trial in that relapsed/refractory JAK -- previously exposed JAK population. And now, of course, you have the Phase I data specifically evaluating SELINEXOR in combination with ruxolitinib. So when I evaluate our opportunity and the strength of the data, it's really looking at all of those data sets that really inform the potential of SELINEXOR in myelofibrosis.
What we also know from both patients, as well as physicians is that the efficacy has to extend beyond just those SVR35 and TSS50 rates. I add that because we're also seeing very impressive durability. At the time of the most recent data cutoff, none of the patients had actually progressed either from an SVR35 standpoint or TSS50. So what we are seeing is remarkable SVR35 and TSS50 rates, as well as the corresponding durability that extend well beyond that week 24 time point.
Lastly, I'll mention in terms of 044, Yes, we did push out the time lines a little bit. Now, we are looking at end of '24, beginning of '25. It's a smaller patient population. So these are still JAK-naive patients.
However, their platelet count needs to be within that 50 to 100. So it is a smaller population as compared to that patient population enrolling in the Phase III. Still lots of enthusiasm, and we look forward to providing data from that study shortly.
That's really helpful. I guess I was thinking if the effect size in the Phase III was maybe even more robust than what you had seen in the Phase II, if there might be an opportunity to maintain powering, but cut the trial size down a bit and accelerate time lines there?
Yes. It's a good question. I mean, we are completely blinded to the results, so that's not something that we can do. But like all of our Phase IIIs, we do have an independent DMC that is evaluating the results.
And based upon their assessment, we'll certainly consider if that opportunity exists for the trial.
Thanks, Brian.
[Operator instructions] Last question on the line will be coming from Jonathan Chang from Leerink Partners.
Matt Cowper -- Analyst
Great. Hi, guys. This is Matt on for Jonathan. Thanks for taking my question.
Just looking at some of the details of the cash runway, including the liquidity covenant, etc., how confident are you that you have sufficient cash from a way to get to the updated endometrial cancer top line readout? And how should we be thinking about the monetization of assets such as KPT-9274 as it relates to making the time line work? And lastly, can you comment if there are other programs in the pipeline with similar potential for out-licensing such as 9274.
Yes. Thanks for the question. I'll let Mike talk to the first part, and then I can jump into the second and third question.
Sure. So a reminder, our previous cash runway was into the end of 2025. We've tightened our 2024 opex guidance to be $250 million to $265 million, which includes $20 million of stock comp, which is down from $260 million to $280 million previously. And part of that lowering expenses was the plan resizing with our EM 29 trial and just a continued discipline on operating costs.
Because yes, we realized the importance of extending that cash runway. We have three pivotal readouts. First one is myeloma, which is in the first half of 2025. Second one is myelofibrosis in the second half of 2025 and the third in endometrial in early 2026.
So putting all those together, our cash runway gets us into the early 2026, excluding the convert that we have due in October 2025.
Yes. And I think if we build on, as you mentioned, talking about KPT-9274, it's a novel first-in-class oral small molecule dual inhibitor of PAK4 and MPG that was discovered by Karyopharm and is part of our early stage programs. So obviously, recently, as we announced today, we were able to receive both rare pediatric disease designation and orphan drug disease designation. So I think a really strong opportunity where we're going to be looking to partner or out-license that asset to make sure that we can recognize the full value of it and help to work to bring it to patients or enable someone else to work to bring to patients.
So that's a strong opportunity for us, obviously, with some strong value behind it, given those designations and given the high unmet need in both rhabdosarcoma and Ewing sarcoma. Also, I think as we talked to before, we have ELTANEXOR, which is our second novel sign compound, which we will look at potential partnerships in terms of that asset across the globe. Right now, it's currently partnered just in Asia Pac. So that gives us optionality to look at moving forward.
And then, yes, we have a couple of other assets within the pipeline that we're always opportunistic to see what's the best way to recognize value from those assets. So I think some good optionality in terms of our BD area and obviously with KPT-9274 and the recognition and the areas we've just been recognized by the FDA, I think that adds significant value and looking to recognize that value.
Got it. Thank you so much.
There are no further questions at this time. I'd now like to turn the call back over to Mr. Richard Paulson for final closing comments.
Thank you, operator, and thank you, everyone, for joining us on today's call. We are focused on accelerating the momentum as we look to deliver on our next phase of growth, and our people continue to strive each day for patients with high unmet needs as we work to generate value for patients and shareholders. We thank you for joining again, and have a great day, everyone.
[Operator signoff]
Duration: 0 minutes
Call participants:
Maurice Raycroft -- Analyst
More KPTI analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
Invest Smarter with The Motley Fool
Join over half a million premium members receiving….
- New Stock Picks Each Month
- Detailed Analysis of Companies
- Model Portfolios
- Live Streaming During Market Hours
- And Much More
Motley Fool Investing Philosophy
- #1 Buy 25+ Companies
- #2 Hold Stocks for 5+ Years
- #3 Add New Savings Regularly
- #4 Hold Through Market Volatility
- #5 Let Winners Run
- #6 Target Long-Term Returns
Why do we invest this way? Learn More
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/06/2024.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Three coastlines. One focus.
Find out how we support Canadian asset managers and owners
Securities Finance Solutions
Unlock the full potential of your portfolio
Recent insights
Canadian pension returns.
Including RBC Investor Services’ defined benefit pension clients spanning private and public plans
RBC Financial Markets Monthly
The July 2024 edition of Financial Markets Monthly from RBC Economics includes a forward-looking analysis of Canadian, US and international financial market trends.
Future-proofing securities lending
Securities Finance Times caught up with Kyle Kolasingh, Head of Market Services Solutions, following the recent Canadian Securities Lending Association (CASLA) Annual Conference in Toronto.
Long-standing experience and expertise
Global scale, scope and strength.
Moody's/S&P Credit Rating
assets under administration
Largest bank
in Canada by market capitalization
years in providing investor services
Data as of Q2 2024
Your partner today and tomorrow
For more than 125 years, RBC Investor Services has delivered asset servicing solutions to Canadian asset managers and asset owners, investment counsellors and other financial institutions. Part of Royal Bank of Canada, the country’s largest bank and one of the top 10 globally based on market capitalization, 1 our focus is on safeguarding the assets of our clients and supporting their growth.
Learn more about RBC Investor Services
(1) Based on market capitalization as at April 30, 2024
- How We Help
- Our Insights
- Citizenship
- Client Sign In
- Global Market Information
- News and Events
- Operating Committee
Events & Presentations
Upcoming events.
There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.
Past Events
Huntington bancshares 2024 second quarter earnings conference call / webcast.
A telephone replay is available until Friday, July 26, 2024, at (877) 660-6853 or (201) 612-7415; conference ID #13747594.
2024 Morgan Stanley US Financials, Payments and CRE Conference
Huntington bancshares 2024 first quarter earnings conference call / webcast, 2024 annual meeting of shareholders, rbc capital markets 2024 global financial institutions conference, presentations.
2024 Second Quarter Earnings Review
2024 Second Quarter Investor Presentation
2024 First Quarter Earnings Review
2023 Fourth Quarter Earnings Review
2023 Fourth Quarter Investor Presentation
BancAnalysts Association of Boston Conference
2023 Third Quarter Earnings Review
2023 Second Quarter Earnings Review
2023 Morgan Stanley US Financials, Payments and CRE Conference
2023 Second Quarter Investor Presentation
2023 First Quarter Earnings Review
Huntington Bancshares 2023 Annual Meeting of Shareholders
2023 Bank of America Financial Services Conference Presentation
2022 Fourth Quarter Earnings Review
2022 Investor Day Presentation
2022 Third Quarter Earnings Review
2022 Second Quarter Earnings Review
The 2022 Morgan Stanley US Financials, Payments, & CRE Conference
2022 First Quarter Earnings Review
Huntington Bancshares 2022 Annual Meeting of Shareholders
RBC Capital Markets Global Financial Institutions Conference
2021 Fourth Quarter Earnings Review
Goldman Sachs 2021 US Financial Services Conference
2021 Bank of America Securities Banking and Financials Conference
Barclays Global Financial Services Conference
2021 Third Quarter Investor Presentation
2021 Morgan Stanley US Financials, Payments & CRE Conference
2021 Second Quarter Investor Presentation
2021 RBC Capital Markets Financial Institutions Conference
2021 First Quarter Investor Presentation
Huntington Bancshares and TCF Financial Corporation Announce Merger To Create Top 10 U.S. Regional Bank
2020 Fourth Quarter Investor Presentation
2020 Third Quarter Investor Presentation
Morgan Stanley Virtual U.S. Financials Conference
2020 Second Quarter Investor Presentation
RBC Capital Markets Fixed Income Symposium
RBC Capital Markets 2020 Financial Institutions Conference
2020 First Quarter Investor Presentation
Goldman Sachs 2019 US Financial Services Conference
2019 Fourth Quarter Investor Presentation
Barclays 2019 Global Financial Services Conference
Nasdaq’s 40th Investor Conference in London
Deutsche Bank Global Financial Services Conference
RBC Capital Markets Financial Institutions Conference
The Bernstein Sixth Annual Financials Summit
- Email Alerts
- Company Profile
- RSS News Feed
- Go to Personal Banking Home Page
- Go to Small Business Banking Home Page
- Go to Wealth Management Banking Home Page
- Go to Businesses & Institutions Banking Home Page
- Current section About Key Banking Home Page
Events & Presentations
| Disclaimer: Please note: Information contained in these presentation materials is disseminated only as of the date of the particular presentation and is not necessarily updated by the company. Any opinions, estimates or forecasts regarding KeyCorp's performance made by management are only made as of the presentation date. Forward-looking statements The conference call and discussion including related questions and answers, and presentation materials, contain "forward-looking statements" about issues like anticipated improvement in earnings, expected expense reductions and revenue growth, and related objectives. Forward-looking statements by their nature are subject to assumptions, risks and uncertainties. For a variety of reasons, actual results could differ materially from those contained in or implied by the forward-looking statements: |
Goldman Sachs Presentation at the RBC Global Financial Institutions Conference 2023
David Solomon, Chairman and Chief Executive Officer, is scheduled to present at the RBC Global Financial Institutions Conference 2023 on Tuesday, March 7, 2023, at 9:20 a.m. (ET).
David M. Solomon Chairman and CEO Read Bio
Cautionary Note on Forward-Looking Statements
Today’s presentation includes forward-looking statements. These statements are not historical facts, but instead represent only the Firm’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of the Firm’s control. Forward-looking statements include statements about backlog, potential revenue and growth opportunities. It is possible that the Firm’s actual results, including the incremental revenues, if any, from such opportunities, and financial condition, may differ, possibly materially, from the anticipated results, financial condition and incremental revenues indicated in these forward-looking statements.
For a discussion of some of the risks and important factors that could affect the Firm’s future results and financial condition, see “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. You should also read the forward-looking disclaimers in our Form 10-Q, particularly as it relates to capital and leverage ratios, and information on the calculation of non-GAAP financial measures that is posted on the Investor Relations portion of our website: www.gs.com . Statements about our revenue and growth opportunities are subject to the risk that the Firm’s businesses may be unable to generate additional incremental revenues or take advantage of growth opportunities.
The statements in the presentation are current only as of its date, March 7, 2023.
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy . You can opt-out at any time.
Investor Centre
| Event | Webcast |
|---|---|
| 2024 Laurentian Bank Investor Day (1:00 PM ET) | Replay (English) |
| 2024 Annual Meeting of Shareholders | Replay (EN) |
| Éric Provost @ RBC Capital Markets Canadian Bank CEO Conference (2:35 PM ET) | Webcast |
| 2023 Annual Meeting of Shareholders | Replay (Original language) |
| Rania Llewellyn, President and CEO of Laurentian Bank to speak at the 21st Annual National Bank Financial Services Conference at 3:35 PM (ET) | Webcast |
| Rania Llewellyn, President and CEO, will speak at the 2023 RBC Capital Markets Canadian Bank CEO Conference at 1:55 p.m. (ET) | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank - Audio webcast |
| Rania Llewellyn, President and CEO, will speak at the 2022 Scotiabank Financials Summit at 1:30 p.m. (ET) | Webcast |
| 2022 Annual Meeting of Shareholders | Annual Meeting of Shareholders (audio) |
| Rania Llewellyn, President and CEO, will speak at the 20th National Bank Financial Annual Canadian Financial Services Conference (3:35 p.m. ET) | Webcast link |
| Rania Llewellyn, President and CEO, will speak at the 25th Annual CIBC Western Institutional Investor Conference (10:05 a.m. ET) | |
| Rania Llewellyn, President and CEO, will speak at the 2022 RBC Capital Markets Canadian Bank CEO Conference at 3:20 p.m. (ET) | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank |
| Laurentian Bank Investor Day | |
| Pre-announcement of Certain Q4-21 Charges | Presentation by Rania Llewellyn, President and Chief Executive Officer and Yvan Deschamps, Executive Vice President,Chief Financial Officer |
| BMO CEO Lunch Series | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group |
| Rania Llewellyn, President and CEO, will speak at the 2021 Scotiabank Financials Summit at 11:30 a.m. | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group |
| 2021 Annual Meeting of Shareholders | Remarks of Michael Mueller |
| National Bank Financial 19th Annual Canadian Financial Services Conference | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group |
| RBC Capital Markets Canadian Bank CEO Conference | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group |
| 2020 Annual Meeting of Shareholders | Remarks of Michael Mueller |
| CIBC 18th Annual Eastern Institutional Investor Conference | Discussion with François Desjardins, President and Chief Executive Officer at Laurentian Bank Financial Group |
| 2019 Annual Meeting of Shareholders | 2019 Annual Meeting of Shareholders - Remarks of François Desjardins |
| Mortgage Review conference call | |
| 2018 Annual Meeting of Shareholders | |
| Acquisition of Northpoint Commercial Finance | |
| 2017 Annual Meeting of Shareholders | |
| Acquisition of CIT’s Canadian Equipment Financing & Corporate Financing Activities | |
| Annual Shareholder’s Meeting 2016 | |
| Laurentian Bank Investor Forum January 26, 2016 – 9:15 am (ET) | To listen to the conference, click here. |
| Event | Presentations |
|---|---|
| 2024 Laurentian Bank Investor Day (1:00 PM ET) | Full Presentation |
| 2024 Annual Meeting of Shareholders | Remarks - Éric Provost |
| Éric Provost @ RBC Capital Markets Canadian Bank CEO Conference (2:35 PM ET) | |
| 2023 Annual Meeting of Shareholders | Transcript - Presentation of Rania Llewellyn |
| Rania Llewellyn, President and CEO of Laurentian Bank to speak at the 21st Annual National Bank Financial Services Conference at 3:35 PM (ET) | |
| Rania Llewellyn, President and CEO, will speak at the 2023 RBC Capital Markets Canadian Bank CEO Conference at 1:55 p.m. (ET) | |
| Rania Llewellyn, President and CEO, will speak at the 2022 Scotiabank Financials Summit at 1:30 p.m. (ET) | |
| 2022 Annual Meeting of Shareholders | Meeting Transcript - As delivered |
| Rania Llewellyn, President and CEO, will speak at the 20th National Bank Financial Annual Canadian Financial Services Conference (3:35 p.m. ET) | Presentation by Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank |
| Rania Llewellyn, President and CEO, will speak at the 25th Annual CIBC Western Institutional Investor Conference (10:05 a.m. ET) | |
| Rania Llewellyn, President and CEO, will speak at the 2022 RBC Capital Markets Canadian Bank CEO Conference at 3:20 p.m. (ET) | Presentation by Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank |
| Laurentian Bank Investor Day | |
| Pre-announcement of Certain Q4-21 Charges | Pre-announcement of Certain Q4-21 Charges |
| BMO CEO Lunch Series | |
| Rania Llewellyn, President and CEO, will speak at the 2021 Scotiabank Financials Summit at 11:30 a.m. | |
| 2021 Annual Meeting of Shareholders | Remarks of Michael Mueller |
| National Bank Financial 19th Annual Canadian Financial Services Conference | Investor Presentation at National Bank Financial 19th Annual Canadian Financial Services Conference |
| RBC Capital Markets Canadian Bank CEO Conference | Investor Presentation at RBC Capital Markets Canadian Bank CEO Conference |
| 2020 Annual Meeting of Shareholders | Remarks of Michael Mueller |
| CIBC 18th Annual Eastern Institutional Investor Conference | |
| 2019 Annual Meeting of Shareholders | 2019 Annual Meeting of Shareholders - Remarks of Isabelle Courville |
| Mortgage Review conference call | Mortgage Review - Presentation |
| 2018 Annual Meeting of Shareholders | 2018 Annual Meeting of Shareholders - Remarks of Isabelle Courville |
| Acquisition of Northpoint Commercial Finance | Acquisition of Northpoint Commercial Finance |
| 2017 Annual Meeting of Shareholders | 2017 Annual Meeting of Shareholders - Remarks of Isabelle Courville |
| Acquisition of CIT’s Canadian Equipment Financing & Corporate Financing Activities | Acquisition of CIT's Canadian Equipment Financing & Corporate Financing Activities |
| Annual Shareholder’s Meeting 2016 | Annual Shareholder's Meeting 2016 - Remarks of Isabelle Courville |
| Laurentian Bank Investor Forum January 26, 2016 – 9:15 am (ET) | Laurentian Bank Investor Forum |
| Event | Webcast | Presentations & Speeches |
|---|---|---|
| 2024 Laurentian Bank Investor Day (1:00 PM ET) | Replay (English) Replay (French) | Full Presentation Strategic Plan Financial Presentation |
| 2024 Annual Meeting of Shareholders | Replay (EN) Replay (Original language) Voting results | Remarks - Éric Provost Remarks - Michael T. Boychuk Voting results |
| Éric Provost @ RBC Capital Markets Canadian Bank CEO Conference (2:35 PM ET) | Webcast | |
| 2023 Annual Meeting of Shareholders | Replay (Original language) Replay (English) | Transcript - Presentation of Rania Llewellyn |
| Rania Llewellyn, President and CEO of Laurentian Bank to speak at the 21st Annual National Bank Financial Services Conference at 3:35 PM (ET) | Webcast Replay link | |
| Rania Llewellyn, President and CEO, will speak at the 2023 RBC Capital Markets Canadian Bank CEO Conference at 1:55 p.m. (ET) | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank - Audio webcast | |
| Rania Llewellyn, President and CEO, will speak at the 2022 Scotiabank Financials Summit at 1:30 p.m. (ET) | Webcast | |
| 2022 Annual Meeting of Shareholders | Annual Meeting of Shareholders (audio) | Meeting Transcript - As delivered Meeting Transcript - English Remarks of Rania Llewellyn |
| Rania Llewellyn, President and CEO, will speak at the 20th National Bank Financial Annual Canadian Financial Services Conference (3:35 p.m. ET) | Webcast link | Presentation by Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank |
| Rania Llewellyn, President and CEO, will speak at the 25th Annual CIBC Western Institutional Investor Conference (10:05 a.m. ET) | ||
| Rania Llewellyn, President and CEO, will speak at the 2022 RBC Capital Markets Canadian Bank CEO Conference at 3:20 p.m. (ET) | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank | Presentation by Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank |
| Laurentian Bank Investor Day | ||
| Pre-announcement of Certain Q4-21 Charges | Presentation by Rania Llewellyn, President and Chief Executive Officer and Yvan Deschamps, Executive Vice President,Chief Financial Officer | Pre-announcement of Certain Q4-21 Charges Conference call transcript |
| BMO CEO Lunch Series | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group | |
| Rania Llewellyn, President and CEO, will speak at the 2021 Scotiabank Financials Summit at 11:30 a.m. | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group | |
| 2021 Annual Meeting of Shareholders | Remarks of Michael Mueller Remarks of Rania Llewellyn Annual Meeting of Shareholders | Remarks of Michael Mueller Remarks of Rania Llewellyn |
| National Bank Financial 19th Annual Canadian Financial Services Conference | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group | Investor Presentation at National Bank Financial 19th Annual Canadian Financial Services Conference |
| RBC Capital Markets Canadian Bank CEO Conference | Discussion with Rania Llewellyn, President and Chief Executive Officer of Laurentian Bank Financial Group | Investor Presentation at RBC Capital Markets Canadian Bank CEO Conference |
| 2020 Annual Meeting of Shareholders | Remarks of Michael Mueller Remarks of François Desjardins Annual Meeting of Shareholders | Remarks of Michael Mueller Remarks of François Desjardins Transcript of the Annual Meeting of Shareholders |
| CIBC 18th Annual Eastern Institutional Investor Conference | Discussion with François Desjardins, President and Chief Executive Officer at Laurentian Bank Financial Group | |
| 2019 Annual Meeting of Shareholders | 2019 Annual Meeting of Shareholders - Remarks of François Desjardins | 2019 Annual Meeting of Shareholders - Remarks of Isabelle Courville 2019 Annual Meeting of Shareholders - Remarks of Michael Mueller 2019 Annual Meeting of Shareholders - Remarks of François Desjardins |
| Mortgage Review conference call | Mortgage Review - Presentation | |
| 2018 Annual Meeting of Shareholders | 2018 Annual Meeting of Shareholders - Remarks of Isabelle Courville 2018 Annual Meeting of Shareholders - Remarks of François Desjardins 2018 Annual Meeting of Shareholders - Remarks of François Laurin | |
| Acquisition of Northpoint Commercial Finance | Acquisition of Northpoint Commercial Finance | |
| 2017 Annual Meeting of Shareholders | 2017 Annual Meeting of Shareholders - Remarks of Isabelle Courville 2017 Annual Meeting of Shareholders - Remarks of François Desjardins 2017 Annual Meeting of Shareholders - Remarks of François Laurin | |
| Acquisition of CIT’s Canadian Equipment Financing & Corporate Financing Activities | Acquisition of CIT's Canadian Equipment Financing & Corporate Financing Activities | |
| Annual Shareholder’s Meeting 2016 | Annual Shareholder's Meeting 2016 - Remarks of Isabelle Courville Annual Shareholder's Meeting 2016 - Remarks of François Desjardins Annual Shareholder's Meeting 2016 - Remarks of François Laurin | |
| Laurentian Bank Investor Forum January 26, 2016 – 9:15 am (ET) | To listen to the conference, click here. | Laurentian Bank Investor Forum |
© 2024 Laurentian Bank. All rights reserved.
- Legal Notice
- Cookie Policy
- About this Website
Conferences
featured conferences.
Pharmaceutical Development, Manufacturing and Bioprocessing Conference
Global Industrials Conference
Precious Metals Conference
- Upcoming Conferences
- Past Conferences
| Event date | Event description | Event location |
|---|---|---|
| 23-24 | Pharmaceutical Development, Manufacturing and Bioprocessing Conference | Virtual |
| 24-25 | Global Industrials Conference | Las Vegas |
| 24-25 | Global Communications Infrastructure Conference | Chicago |
| 12 | Precious Metals Conference | London |
| 19-20 | Technology, Internet, Media and Telecommunications Conference | New York |
| 03 | Forest Products Conference | Toronto |
| 07 | Canadian Bank CEO Conference | Toronto |
| 04-05 | Global Financial Institutions Conference | New York |
| 20-21 | Ophthalmology Conference | Virtual |
| 15 | Technology Private Company Conference | Beverly Hills |
| 20-21 | Global Healthcare Conference | New York |
| 03-04 | Global Energy, Power & Infrastructure Conference | New York |
| 10 | Financial Technology Conference | New York |
| Event date | Event description | Even location |
|---|---|---|
| 03 | RBC Consumer & Retail Conference | London |
| 18 | Canadian Private Technology Conference | Toronto |
| 13-14 | Global Mining & Materials Conference | New York |
| 11 | FinTech Conference | New York |
| 06 | Consumer Day | New York |
| 05-06 | Investor Sessions for CAD REITs and REOCs | New York |
| 04-05 | Global Energy, Power & Infrastructure Conference | New York |
| 14 | Sustainable Aviation Fuels Symposium | London |
| 14-15 | Global Healthcare Conference | New York |
| 14-16 | Canadian Industrials Conference | Toronto |
| 09 | Technology Private Company Conference | Beverly Hills |
| 05-06 | Global Financial Institutions Conference | New York |
| 09 | Canadian Bank CEO Conference | Toronto |
| 13-14 | Healthcare Private Company Conference | Virtual |
| 05 | Forest Products Conference | Toronto |
| 14-15 | Technology, Internet, Media & Telecommunications Conference | New York |
| 27-28 | Global Communications Infrastructure Conference | Chicago |
| 12-13 | Global Industrials Conference | Las Vegas |
| 07 | Global Engineering, Construction & Infrastructure Solutions Conference | Virtual |
| 27 | Canadian Private Technology Conference | Toronto |
| 15-16 | Global Mining & Materials Conference | New York |
| 15 | Canadian Asset Manager Conference | Virtual |
| 13 | Financial Technology Conference | New York |
| 08 | Consumer Day | New York |
| 07-08 | Canadian REITs & REOCs Investor Sessions | New York |
| 06-07 | Global Energy, Power & Infrastructure Conference | New York |
| 06-07 | Canadian Housing & Mortgage Conference | Virtual |
| 16-17 | Global Healthcare Conference | New York |
| 10 | Technology Private Company Conference | Beverly Hills |
| 20 | Battery Value Chain Conference | London |
| 11 | Private HCIT and Digital Health Conference | Virtual |
| 29-30 | Global Environmental, Social and Governance Conference | Virtual |
| 07-08 | Financial Institutions Conference | New York |
| 09 | Canadian Bank CEO Conference | Toronto |
Conference Attendance
As all conferences are by invitation only, please contact your RBC Capital Markets representative for more information.
Accessibility Quick Links
- Skip to Online Banking
- Skip to Content
- Skip to Navigation
- Skip to Sub Navigation
Are you sure you want to delete this saved card number?
- Investor Relations
- Events and Presentations
Events and presentations
June 7, 2024
Event: TD Financial Services & Fintech Summit
Speaker: Hratch Panossian, Senior Executive Vice-President and Head of Personal and Business Banking, Canada
Time: 10:20 am to 10:50 am ET
Play webcast Opens in a new window.
March 26, 2024
Event: National Bank Financial Markets 22 nd Annual Financial Services Conference
Speaker: Shawn Beber, Senior Executive Vice-President and Group Head, U.S. Region; President and CEO, CIBC Bank USA
Time: 10:30 am to 10:55 am ET
Register for webcast Opens in a new window.
March 6, 2024
Event: 2024 RBC Capital Markets Global Financial Institutions Conference Fireside Chat
Speaker: Hratch Panossian, Senior Executive Vice-President and Chief Financial Officer
Time: 10:00 am to 10:30 am ET
January 9, 2024
Event: 2024 RBC Capital Markets Canadian Bank CEO Conference
Speaker: Victor Dodig, President and Chief Executive Officer
Time: 12:40 pm to 1:15 pm ET
Register for webcast Opens in a new window.
September 13, 2023
Event: Barclays Global Financial Services Conference 2023
Time: 9:45 am to 10:25 am ET
September 6, 2023
Event: 2023 Scotiabank Financials Summit
Speaker: Victor Dodig, President and Chief Executive Officer
Time: 12:30 pm to 1:05 pm ET
March 29, 2023
Event: National Bank Financial Markets 21 st Annual Financial Services Conference
Speaker: Jon Hountalas, Senior Executive Vice-President and Group Head, Canadian Banking
Time: 9:10 am to 9:35 am ET
March 8, 2023
Event: 2023 RBC Capital Markets Global Financial Institutions Conference Fireside Chat
Speaker: Hratch Panossian, Senior Executive Vice-President and Chief Financial Officer
Time: 10:00 am to 10:30 am ET
January 9, 2023
Event: 2023 RBC Capital Markets Canadian Bank CEO Conference
Time: 12:35 pm to 1:10 pm ET
September 12, 2022
Event: Barclays Global Financial Services Conference 2022
Time: 10:30 am to 11:10 am ET
September 7, 2022
Event: 2022 Scotiabank Financials Summit
Time: 10:25 am to 11:00 am ET
June 16, 2022
Event: CIBC Investor Day
Time: 8:30 am to 2:00 pm ET
2022 CIBC Investor Day Opens in a new window.
March 22, 2022
Event: National Bank Financial Markets 20th Annual Financial Services Conference
Speaker: Jon Hountalas, Senior Executive Vice-President and Group Head, Commercial Banking and Wealth Management, Canada
March 9, 2022
Event: 2022 RBC Capital Markets Global Financial Institutions Conference Fireside Chat with Darko Mihelic
Speaker: Laura Dottori-Attanasio, Senior Executive Vice-President and Group Head, Personal and Business Banking, Canada
Time: 10:40 am to 11:10 am ET
January 10, 2022
Event: 2022 RBC Capital Markets Canadian Bank CEO Conference
Speaker: Victor Dodig, President and Chief Executive Officer
Time: 10:15 am to 10:45 am ET
October 27, 2021
Event: BMO Capital Markets Bank Blitz
Time: 12:30 pm to 1:45 pm ET
September 15, 2021
Event: Barclays Global Financial Services Conference 2021
Speaker: Hratch Panossian, Senior Executive Vice-President and Chief Financial Officer
September 9, 2021
Event: 2021 Scotiabank Financials Summit
Time: 10:30 am to 10:55 am ET
June 28, 2021
Event: CIBC Capital Markets Fireside Chat with Paul Holden
Time: 12:00 pm to 1:00 pm ET
Note for CIBC employees: Please watch on a personal device outside of the CIBC network – VPN and Citrix.
March 24, 2021
Event: National Bank Financial Markets 19th Annual Financial Services Conference
Speaker: Shawn Beber, Senior Executive Vice-President and Chief Risk Officer
Time: 9:10 to 9:45 am ET
March 9, 2021
Event: RBC Capital Markets Global Financial Institutions Conference Fireside Chat with Darko Mihelic
Time: 11:20 to 11:50 am ET
January 27, 2021
Event: Virtual event at Canadian Club — Building a Sustainable and Inclusive Economy for the Future
Time: 12:30 pm to 1:30 pm ET
January 11, 2021
Event: 2021 RBC Capital Markets Canadian Bank CEO Conference
Time: 10:15 am to 10:45 am ET
October 15, 2020
Shawn Beber, Senior Executive Vice-President and Chief Risk Officer, spoke at the CIBC Capital Markets Virtual Fireside Chat.
October 14, 2020
Victor Dodig, President and Chief Executive Officer, spoke at the BMO Virtual CEO Bank Blitz.
The replay is available until January 12, 2021.
September 22, 2020
Laura Dottori-Attanasio, Senior Executive Vice-President and Group Head, Personal and Business Banking, Canada, spoke at the 2020 BMO Digital Banking Summit.
Play webcast Opens a new window.
September 9, 2020
Victor Dodig , President and Chief Executive Officer, spoke at the 2020 Scotiabank Financials Summit.
July 16, 2020
Victor Dodig, President and Chief Executive Officer, spoke at a fireside chat with RBC Analyst, Darko Mihelic.
June 23, 2020
Hratch Panossian, Senior Executive Vice-President and Chief Financial Officer, spoke at the TD Securities Management Speaker Series, Fireside Chat with CIBC.
Play webcast Opens a new window in your browser.
Password: CIBC
January 7, 2020
Victor Dodig, President and Chief Executive Officer, spoke at the 2020 RBC Capital Markets Canadian Bank CEO Conference.
November 1, 2019
Victor Dodig, President and Chief Executive Officer, gave the keynote address to the Economic Club of Canada (Calgary).
The Importance of Canada's Energy Sector (PDF, 170 KB) Opens a new window in your browser.
September 25, 2019
Victor Dodig, President and Chief Executive Officer, spoke at the 2019 CIBC Eastern Institutional Investor Conference (Montreal).
September 10, 2019
Jon Hountalas, Senior Executive Vice-President and Group Head, Commercial Banking and Wealth Management, Canada, spoke at the 2019 Barclays Global Financial Services Conference (New York).
September 4, 2019
Victor Dodig, President and Chief Executive Officer, spoke at the 2019 Scotiabank Financials Summit.
April 11, 2019
Victor Dodig, President and Chief Executive Officer, gave the keynote address to the Public Policy Forum.
Canadian Leadership in the Global Economy – Today and Tomorrow (PDF, 220 KB) Opens a new window in your browser.
March 27, 2019
Jon Hountalas, Senior Executive Vice-President and Group Head, Commercial Banking and Wealth Management, Canada, spoke at the National Bank Financial Markets 17 th Annual Financial Services Conference (Montreal).
January 8, 2019
Victor Dodig, President and Chief Executive Officer, spoke at the 2019 RBC Capital Markets Bank CEO Conference.
September 26, 2018
Victor Dodig, President and Chief Executive Officer, spoke at the 2018 CIBC Eastern Institutional Investor Conference (Montreal).
September 12, 2018
Christina Kramer, Senior Executive Vice President and Group Head, Personal and Small Business Banking, and Laura Dottori-Attanasio, Senior Executive Vice President and Chief Risk Officer, spoke at the 2018 Barclays Global Financial Services Conference (New York).
September 11, 2018
Victor Dodig, President and Chief Executive Officer, gave the keynote address on Solutions for Sustained Prosperity to the Empire Club of Canada.
Play webcast Opens a new window in your browser
Keynote Presentation (PDF, 90 KB) Opens a new window in your browser.
September 5, 2018
Victor Dodig, President and Chief Executive Officer, spoke at the 2018 Scotiabank Financials Summit.
March 28, 2018
Christina Kramer, Senior Executive Vice President and Group Head, Personal and Small Business Banking, spoke at the 2018 National Bank Financial Services Conference.
Play webcast Play webcast. Opens a new window in your browser
January 9, 2018
Victor Dodig, President and Chief Executive Officer, spoke at the 2018 RBC Capital Markets Canadian Bank CEO Conference.
December 13, 2017
CIBC Investor Day (PDF, 1.6 MB) Opens a new window in your browser.
CIBC held an Investor Day to provide investors and analysts with an update on the bank's growth strategy.
September 27, 2017
Victor Dodig, President and Chief Executive Officer, spoke at CIBC's 16 th Annual Eastern Institutional Investor Conference (Montreal).
September 11, 2017
Victor Dodig, President and Chief Executive Officer, and Larry Richman, Group Head, US Region and President and CEO, The PrivateBank, spoke at the 2017 Barclays Global Financial Services Conference (New York).
September 6, 2017
Victor Dodig, President and Chief Executive Officer, spoke at the 2017 Scotiabank Financials Summit.
March 30, 2017
David Williamson, Senior Executive Vice President and Group Head, Retail and Business Banking, spoke at the 2017 National Bank Financial Services Conference.
January 10, 2017
Victor Dodig, President and Chief Executive Officer, spoke at the 2017 RBC Capital Markets Canadian Bank CEO Conference.
September 21, 2016
Victor Dodig, President and Chief Executive Officer, spoke at CIBC’s 15 th Annual Eastern Institutional Investor Conference (Montreal).
September 7, 2016
Victor Dodig, President and Chief Executive Officer, spoke at the 2016 Scotiabank Financials Summit.
June 29, 2016
CIBC to acquire PrivateBancorp, Inc.
Open Slides (PDF, 635 KB) Opens a new window in your browser.
March 31, 2016
Laura Dottori-Attanasio, Senior Executive Vice President and Chief Risk Officer, spoke at the National Bank Financial 14 th Annual Canadian Financial Services Conference (Montreal).
Play webcast
January 12, 2016
Victor Dodig, President and Chief Executive Officer, spoke at the 2016 RBC Capital Markets Canadian Bank CEO Conference.
October 7, 2015
CIBC Investor Day (PDF, 1.7 MB) Opens a new window in your browser.
Hosted by Victor Dodig, President and Chief Executive Officer.
Speakers’ biographies (PDF, 505 KB) Opens a new window in your browser.
Agenda (PDF, 60 KB) Opens a new window in your browser.
September 18, 2015
Laura Dottori-Attanasio, Senior Executive Vice President and Chief Risk Officer, presented at Barclays 2015 Global Financial Services Conference (New York).
September 16, 2015
Victor Dodig, President and Chief Executive Officer, presented at CIBC 14 th Annual Eastern Institutional Investor Conference (Montreal).
September 9, 2015
Victor Dodig, President and Chief Executive Officer, presented at Scotiabank GBM Financials Summit (Toronto).
June 23, 2015
Victor Dodig, President and Chief Executive Officer, presented the keynote address on the Future of Banking to the Empire Club of Canada.
March 24, 2015
Harry Culham, Managing Director and Group Co-Head, Wholesale Banking, spoke at the National Bank Financial 13 th Annual Canadian Financial Services Conference.
January 14, 2015
Victor Dodig, President and Chief Executive Officer, spoke at the 2015 RBC Capital Markets’ Canadian Bank CEO Conference.
September 18, 2014
An investment community introduction to CIBC (PDF, 1.2 MB)
This presentation is updated quarterly and provides investors with an overview of CIBC's financial performance, strategic imperatives and key businesses.
September 17, 2014
Victor Dodig, Senior Executive Vice-President, CIBC, and Group Head, Wealth Management, spoke at the CIBC 13 th Annual Eastern Investor Conference.
September 9, 2014
Kevin Glass, Senior Executive Vice-President and Chief Financial Officer, spoke at the Barclays 2014 Global Financial Services Conference.
September 3, 2014
Victor Dodig, Senior Executive Vice-President, CIBC, and Group Head, Wealth Management, spoke at the 2014 Scotiabank Financials Summit.
June 23, 2014
March 26, 2014
David Williamson, Senior Executive Vice-President and Group Head, Retail and Business Banking, spoke at the National Bank Financial 2014 Canadian Financial Services Conference.
March 14, 2014
An investment community introduction to CIBC (PDF, 920 KB)
January 14, 2014
Gerry McCaughey, President and Chief Executive Officer, spoke at the RBC Capital Markets 2014 Canadian Bank CEO Conference.
December 31, 2013
An investment community introduction to CIBC (PDF, 965 KB)
September 20, 2013
An investment community introduction to CIBC (PDF, 1 MB)
September 18, 2013
Gerry McCaughey, President and Chief Executive Officer, spoke at the CIBC 12 th Annual Eastern Institutional Investor Conference.
September 10, 2013
Kevin Glass, Senior Executive Vice-President and Chief Financial Officer, spoke at the 2013 Barclays Global Financial Services Conference in New York .
September 4, 2013
Gerry McCaughey, President and Chief Executive Officer, spoke at the 2013 Scotiabank Financials Summit in Toronto .
Presentation (PDF, 495 KB)
June 18, 2013
An investment community introduction to CIBC (PDF, 590 KB)
June 11, 2013
Victor Dodig, Senior Executive Vice-President, CIBC Wealth Management, gave an address to the Morgan Stanley Financials Conference in New York.
May 23, 2013
Richard Nesbitt, Senior Executive Vice-President, CIBC and Group Head, Wholesale, International, and Technology and Operations, gave an address to the natural resource conference in Tokyo, Japan.
The Canadian Opportunity (PDF, 420 KB)
Speech (PDF, 50 KB)
April 11, 2013
An investment community introduction to CIBC. (PDF, 720 KB)
March 27, 2013
Kevin Glass, Senior Executive Vice-President and Chief Financial Officer gave an address to the NBF 2013 Canadian Financial Services Conference in Montreal .
March 6, 2013
Kevin Glass, Senior Executive Vice-President and Chief Financial Officer, gave an address to the Citi 2013 U.S. Financial Services Conference in Boston .
January 8, 2013
Gerry McCaughey, President and Chief Executive Officer, gave an address to the RBC Capital Markets Canadian Bank CEO Conference .
September 19, 2012
Gerry McCaughey, President and Chief Executive Officer, gave an address to the 11 th Annual Eastern Institutional Investor Conference .
September 11, 2012
Richard Nesbitt, Senior Executive Vice-President CIBC and Group Head Wholesale, International, and Technology and Operations, gave an address to the Barclay’s Capital Global Financial Services Conference.
September 5, 2012
Gerry McCaughey, President and Chief Executive Officer, gave an address to the Scotiabank GBM Financials Summit 2012.
Address to the Scotiabank GBM Financials Summit 2012 (PDF, 240 KB)
June 13, 2012
David Williamson, Senior Executive Vice-President, CIBC, and Group Head, Retail and Business Banking, gave an address to the Morgan Stanley Financials Conference.
North America’s Strongest Bank (PDF, 450 KB)
April 26, 2012
Gerry McCaughey, President and Chief Executive Officer, gave an address to the Annual Meeting of Shareholders.
Address to the Annual Meeting of Shareholders (PDF, 40 KB)
March 29, 2012
Victor Dodig, Senior Executive Vice-President, CIBC, and Group Head, Wealth Management, gave an address to the National Bank Financial Canadian Financial Services Conference.
January 10, 2012
Gerry McCaughey, President and Chief Executive Officer, gave an address to the RBC Capital Markets Canadian Bank CEO Conference.
September 21 to 22, 2012
Gerry McCaughey, President and Chief Executive Officer, presented at the 10 th Annual Eastern Institutional Investor Conference.
September 13, 2011
Kevin Glass, Senior Executive Vice-President and Chief Financial Officer, gave an address to the Barclay’s Capital Global Financial Services Conference.
Address to the Barclay's Capital Global Financial Services Conference (PDF, 175 KB)
September 7, 2011
Gerry McCaughey, President and Chief Executive Officer, gave an address to the Scotia Capital Financials Summit 2011.
Address to the Scotia Capital Financials Summit 2011 (PDF, 185 KB)
July 15, 2011
CIBC Grows Asset Management Business with Investment in American Century Investments (PDF, 65 KB)
March 29, 2011
Richard Nesbitt, Chairman and Chief Executive Officer Wholesale Banking, presented at the National Bank Financial Canadian Financial Services Conference.
February 2, 2011
Richard Nesbitt, Chairman and Chief Executive Officer Wholesale Banking, presented at the Morgan Stanley Financial Services Conference.
September 30, 2010
CIBC Retail Markets senior executives provide an update on the bank's business strategies and priorities (PDF, 2.2 MB)
Transcript (PDF, 255 KB)
September 21 to 23, 2010
Gerry McCaughey, President and Chief Executive Officer, presented at the 9 th Annual Eastern Institutional Investor Conference.
September 15, 2010
Gerry McCaughey, President and Chief Executive Officer, gave an address to the Scotia Capital Financials Summit.
Building a Strong Canadian Bank: Address to the Scotia Capital Financials Summit (PDF, 160 KB)
September 13, 2010
Richard Nesbitt, Chairman and Chief Executive Officer, gave an address to the Barclays Global Financial Services Conference.
Building a Strong Canadian Bank: Address to the Barclays Global Financial Services Conference (PDF, 215 KB)
March 30, 2010
Gerry McCaughey, President and Chief Executive Officer, presented at the National Bank Financial Canadian Financial Services Conference.
National Bank Financial Canadian Financial Services Conference (PDF, 125 KB)
January 14, 2010
Gerry McCaughey, President and Chief Executive Officer, presented at the RBC Capital Markets Canadian Bank CEO Conference.
Forward-looking statement
From time to time, we make written or oral forward-looking statements within the meaning of certain securities laws, including in this site, in filings with Canadian securities regulators or the U.S. Securities and Exchange Commission and in other communications. These statements include, but are not limited to, statements about potential events and about our financial condition, priorities, targets, ongoing objectives, strategies and outlook. A variety of factors, many of which are beyond our control, affect our operations, performance and results and those of our business lines, and could cause actual results to differ materially from the expectations expressed in any of our forward-looking statements. We do not undertake to update any forward-looking statement except as required by law. For further details, refer to the "A Note About Forward Looking Statements" section of our most recent Annual Report and Quarterly Report to Shareholders .
- Common Share Information
- More Information
- 2023 Full Report (PDF, 19.6 MB) Opens in a new window. Opens in a new window.
- Contact Investor Relations
- Quarterly Results
- News Releases
- Share Information
- Debt Information
- Annual Reports and Proxy Circulars
- Annual Meeting
- Regulatory Capital Instruments
Select your country and language
- English United States English. Opens in a new window.
Please note: Multilanguage sites do not provide full access to all content on CIBC.com. The full CIBC website is available in English and French.
- Find a Branch
- Call 1-800-769-2511
- Our Company
- Investor Relations
- News & Stories
- Thought Leadership
Financial Information
Quarterly and annual reports.
| 2024 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | |
|---|---|---|---|---|---|
| Press Release | --> | --> | |||
| Management Comments | --> | --> | |||
| Report to Shareholders | --> | --> | |||
| Quarterly Slides | --> | --> | |||
| Financial Supplement | | | --> | --> | --> |
| Pillar 3 Disclosure | | | --> | --> | --> |
| Webcast | --> |
| 2023 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| Pillar 3 Disclosure | | | | |
| Webcast |
| 2021 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| Pillar 3 Disclosure | | | | |
| Webcast |
| 2020 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | --> | |||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| Pillar 3 Disclosure | | |||
| Webcast | --> |
| 2019 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | --> | |||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| Pillar 3 Disclosure | --> |
| 2017 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | | | ||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | | --> |
| 2016 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | | -->
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | | --> | ||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | | --> |
| 2015 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | | | | |
| Management Comments | | | | |
| Report to Shareholders | | | | |
| Quarterly Slides | | | | | | | | | -->
| Financial Supplement | | | | | | | | | -->
| 2014 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | | --> |
| 2013 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | | |||
| Quarterly Slides | ||||
| Financial Supplement | | | | | --> |
| 2012 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | | |||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | |
| 2011 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | | |||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | |
| 2010 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | | |||
| Report to Shareholders | ||||
| Quarterly Slides | --> | |||
| Financial Supplement | | | | |
| 2009 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | --> | |||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| 2008 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | --> |
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | ||||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| 2007 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | | -->
|---|---|---|---|---|
| Press Release | ||||
| Management Comments | ||||
| Report to Shareholders | | |||
| Quarterly Slides | ||||
| Financial Supplement | | | | --> | --> |
| 2006 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 | | -->
|---|---|---|---|---|
| Press Release | | |||
| Report to Shareholders | | --> | ||
| Quarterly Slides | ||||
| Financial Supplement | | | | |
| 2005 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
| 2004 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
| 2003 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
| 2002 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
| 2001 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
| 2000 Quarterly/Annual Info | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| Report to Shareholders |
Reporting Dates and Call Times
First Quarter February 28 (8:00 a.m. EST)
Instant Replay Details
Second Quarter May 30 (8:30 a.m. EST)
Third Quarter August 28 (8:00 a.m. EST)
Call Details
Fourth Quarter December 4 (8:00 a.m. EST)
2024 Second Quarter Financial Information
Rbc at a glance.
RBC is one of Canada’s largest banks and one of the largest banks in the world, based on market capitalization. Our purpose-driven, principles-led approach means that everything we do centres around building a better future for our clients and communities.
Investor Presentation
Review our financial profile including earnings and revenue, as well as our strategy for future growth.
Legal Disclaimer
Upcoming Events
Capital Tides Investor Cruise 2024
Investor Icebreaker - Resource Exploration Edition
Investor Clubhouse 2025
Past events.
Centurion One Capital 5th Annual LA Summit
Investor Clubhouse at the RBC Canadian Open
Investor Icebreaker - Canucks vs. Flames
Capital Links 2024
ALL-IN: Poker for a Purpose at the PDAC
Indiva Investor Days
Investor Icebreaker (Jan 20)
Indiva Investor Road Shows
Capital Tides Investor Cruise
Emerging Equities VIP Event at the 2023 RBC Canadian Open
Indiva Investor Update - May 23
Investor Series in Vancouver - April 6
York Harbour Metals – Special Investor Presentation
Webinar: Indiva Investor Update
Kudo Snacks Presents: A Gary Payton Meet & Greet and Keynote Event
Toronto Investor Series at The Albany Club
Indiva Quarterly Investor Presentation (Q3 2022)
Emerging Equities VIP Event at the 2022 RBC Canadian Open
Optimi Health Investor Day (April 5)
Volatus Aerospace Broker Luncheon - March 30 (12pm PT/ET)
EXPLORE the WORLD of INDIVA in 2022
Investor Luncheon with Bruce Campbell
Assure Neuromonitoring Investor Presentation
Sign up for event alerts.
COMMENTS
Visit RBC Investor Relations to find details on upcoming and past conferences and investor days, including speakers, presentations and webcasts. ... Investor Day Website; View the Presentation (PDF opens in new window) 2016. City National Investor Day; June 17, 2016 at 9 a.m. (ET)
Access RBC's financial information, share information, investor events and presentations, earnings calls and more at RBC Investor Relations. Skip to main content. Other Sites. Search RBC... Contact Us. Find a Branch; Call 1-800-769-2511; EN. ... RBC Investor Day 2018. Replay the webcast, download the presentation, and more. See Details.
RBC Investor Day 2018. Creating More Value for Clients. ... This webcast is specifically designed for you to both watch and listen to the presentation using your computer during, and after, the event. Replay Webcast Now. Dial-in Access (Audio Only): Canada Toll Free (English): 1 (888) 465-5079;
Webcasts and presentations that have been archived are available by viewing past event details. ... Browse Truist investor-related events and announcements and view previous events. ... A live audio webcast will be available the day of the event on this page. A replay of the webcast will be available on this page for 30 days following the event.
We remain on track to strategically deploy $5.5 billion to $8.5 billion of capital from 2024 to 2026, as outlined at Investor Day, last December. Now, let's turn to slide eight and nine for an ...
RBC Bearings Incorporated will host a webcast on Friday, August 2 nd, 2024, at 11:00 a.m. ET to discuss the quarterly results. To access the webcast, go to the investor relations portion of the Company's website, www.rbcbearings.com, and click on the webcast icon. If you do not have access to the Internet and wish to listen to the call, dial ...
Canada's largest bank by market capitalization(1), with broad leadership in financial services. One of North America's leading diversified financial services companies. Top 10 bank globally based on market capitalization(1), with operations in 29 countries. 97,000+ employees and 17 million clients worldwide. (1) As at January 31, 2023. U.S.
RBC was built via a series of acquisitions led by CEO Dr. Michael Hartnett; The Company has been publicly listed since 2005. ~$8.5B. Market. Facilities in. Estimated percentage of sales that are sole, single or primary sourced. 11 different countries; HQ in Oxford, CT. Capitalization. 54.
Cash generation a primary focus of our management team. Profitability and working capital management has led to long-term growth in free cash flow and improved cash conversion over the last ten years. Cash conversion over 100% of net income last four fiscal years. FY2023 cash conversion 132%.
Investor presentation. March 6, 2023 ©2023 Lincoln National Corporation 2 Forward looking statements - cautionary language ... Risk-Based Capital "RBC" Ratio Over Time. Focused on management actions to rebuild back to 400% RBC Ratio Target. 400% RBC Ratio Target. 452%. 439%. 451%. 427%. 377%. 2018A. 1. 2019A. 1. 2020A.
Elhan Webb-- Senior Vice President, Investor Relations Thank you, Carolyn, and thank you all for joining us on today's conference call to discuss Karyopharm's second quarter Q2 2024 financial ...
About RBC - RBC
Your partner today and tomorrow. For more than 125 years, RBC Investor Services has delivered asset servicing solutions to Canadian asset managers and asset owners, investment counsellors and other financial institutions. Part of Royal Bank of Canada, the country's largest bank and one of the top 10 globally based on market capitalization, 1 ...
RBC Capital Markets 2024 Global Financial Institutions Conference ... 2022 Investor Day Presentation . Oct 21, 2022. 2022 Third Quarter Earnings Review . Jul 21, 2022 . 2022 Second Quarter Earnings Review ... 2020 First Quarter Investor Presentation . Dec 11, 2019. Goldman Sachs 2019 US Financial Services Conference ...
RBC Profile - 2022 4 1 Market Leader: Significant sales from products with #1 or #2 market positions 2 Diversified and Balanced Customer Base: Serving large, industry-leading customers in a wide array of end markets and channels 3 Significant Barriers to Entry: Includes designs, patents, process, brands, qualifications, preference, installed base, and service
Diversity & Inclusion Reporting. Customer Service. 1-800-539-2968. Clients using a TDD/TTY device: 1-800-539-8336. Find a Local Branch or ATM. Contact Us. Company Information. Get to Know Key.
Investor Relations Goldman Sachs Presentation at the RBC Global Financial Institutions Conference 2023. Share share. David Solomon, Chairman and Chief Executive Officer, is scheduled to present at the RBC Global Financial Institutions Conference 2023 on Tuesday, March 7, 2023, at 9:20 a.m. (ET). David M. Solomon Chairman and CEO
Review our financial profile including earnings and revenue, as well as our strategy for future growth. Information contained in the documents, presentations and webcasts made available on this page have been furnished for your information only, is current only as of its date, and may be superseded by more current information.
December 10th, 2021 Laurentian Bank Investor Day. November 23rd, 2021 Pre-announcement of Certain Q4-21 Charges. Presentation by Rania Llewellyn, President and Chief Executive Officer and Yvan Deschamps, Executive Vice President,Chief Financial Officer. Pre-announcement of Certain Q4-21 Charges Conference call transcript.
Toronto. Mar 04-05. Global Financial Institutions Conference. New York. May 15. Technology Private Company Conference. Beverly Hills. Jun 03-04. Global Energy, Power & Infrastructure Conference.
March 29, 2023. Event: National Bank Financial Markets 21st Annual Financial Services Conference. Speaker: Jon Hountalas, Senior Executive Vice-President and Group Head, Canadian Banking. Time: 9:10 am to 9:35 am ET. Play webcast.
1020 Martin Grove Road. Toronto, ON M9W 1J1. Via live webcast online: Webcast. For more information on how to attend the meeting, please see pages 9 through 11 of the Proxy Circular. First preferred shareholders who have already forwarded their voting instructions to their intermediaries do not need to do so again.
2023 Quarterly Reports; 2023 Quarterly/Annual Info Q1 Q2 Q3 Q4; Press Release: View (PDF opens in new window): View (PDF opens in new window): View (PDF opens in new window): Management Comments: View (PDF opens in new window): View (PDF opens in new window): View (PDF opens in new window): Report to Shareholders: View (PDF opens in new window): View (PDF opens in new window)
Investor Clubhouse at the RBC Canadian Open. May 30, 2024 Investor Icebreaker - Canucks vs. Flames ... Indiva Quarterly Investor Presentation (Q3 2022) August 17, 2022 ... Optimi Health Investor Day (April 5) April 5, 2022 Volatus Aerospace Broker Luncheon - March 30 (12pm PT/ET) March 30, 2022 EXPLORE the WORLD of INDIVA in 2022. February 8 ...
This presentation contains forward-looking statements within the meaning of certain securities laws, including the "safe harbour" provisions of the United States Private Securities ... RBC's Q3 2022 Report to Shareholders, and the factors discussed in the Risk section and Impact of COVID-19 and our response section of HSBC Canada's ...
2022 Investor Day (8:00 am ET) Presentation; Webcast; Audio; Transcript; September 21: CIBC Eastern Institutional Investor Conference. September 7 ... RBC Fixed Income Presentation. Presentation; January 10: RBC CEO Conference (2:35 pm MT) Webcast; 2021. October 21: BMO Virtual CEO Bank Blitz: Canadian Western Bank (CWB) September 9